(NASDAQ: ONC) Beigene's forecast annual revenue growth rate of 26.85% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 49.9%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.74%.
Beigene's revenue in 2025 is $3,316,826,000.On average, 4 Wall Street analysts forecast ONC's revenue for 2025 to be $6,700,304,738,200, with the lowest ONC revenue forecast at $6,532,934,163,888, and the highest ONC revenue forecast at $6,870,784,187,491. On average, 4 Wall Street analysts forecast ONC's revenue for 2026 to be $8,125,057,926,929, with the lowest ONC revenue forecast at $7,546,263,855,240, and the highest ONC revenue forecast at $8,538,110,014,632.
In 2027, ONC is forecast to generate $9,339,047,964,890 in revenue, with the lowest revenue forecast at $8,592,567,303,065 and the highest revenue forecast at $10,684,384,159,152.